These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9217787)

  • 1. Misdiagnosis of multiple sclerosis and beta-interferon.
    Poser CM
    Lancet; 1997 Jun; 349(9069):1916. PubMed ID: 9217787
    [No Abstract]   [Full Text] [Related]  

  • 2. [Beta-interferon and multiple sclerosis].
    Clanet M
    Rev Neurol (Paris); 1993; 149(8-9):443-4. PubMed ID: 8009140
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon beta-1a during a first demyelinating event.
    Poser CM
    N Engl J Med; 2001 Jan; 344(3):229; author reply 229-30. PubMed ID: 11188840
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating clinically isolated syndromes suggestive of MS.
    Poser CM
    Lancet; 2007 Dec; 370(9604):2000; author reply 2000-1. PubMed ID: 18083395
    [No Abstract]   [Full Text] [Related]  

  • 5. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
    Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of multiple sclerosis with beta-interferon.
    Poser CM
    Neuroepidemiology; 2008; 31(3):157-8. PubMed ID: 18716413
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon beta treatment for multiple sclerosis.
    Galazka A
    Lancet; 1999 Feb; 353(9151):495; author reply 497-8. PubMed ID: 9989740
    [No Abstract]   [Full Text] [Related]  

  • 8. Magnetic resonance imaging as an outcome measure in the treatment of multiple sclerosis: results of the interferon beta trial.
    Koopmans RA; Paty DW
    Mult Scler; 1995; 1 Suppl 1():S22-3. PubMed ID: 9345393
    [No Abstract]   [Full Text] [Related]  

  • 9. More immunotherapy for multiple sclerosis.
    Hughes RA; Sharrack B
    J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):239-41. PubMed ID: 8795592
    [No Abstract]   [Full Text] [Related]  

  • 10. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta.
    McDonald WI; Miller DH; Thompson AJ
    Ann Neurol; 1994 Jul; 36(1):14-8. PubMed ID: 8024255
    [No Abstract]   [Full Text] [Related]  

  • 11. [Multiple sclerosis in children].
    Deiva K
    Soins; 2009 Nov; (740):49-51. PubMed ID: 20014535
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of multiple sclerosis using recombinant interferon-beta].
    Polman CH; Barkhof F; van Loenen AC; Lucas CJ; Koetsier JC
    Ned Tijdschr Geneeskd; 1994 Jan; 138(1):7-10. PubMed ID: 8289963
    [No Abstract]   [Full Text] [Related]  

  • 13. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
    Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF
    Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Simon JH; Jacobs LD; Campion M; Wende K; Simonian N; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Alam JJ; Fischer JS; Goodkin DE; Granger CV; Lajaunie M; Martens-Davidson AL; Meyer M; Sheeder J; Choi K; Scherzinger AL; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Whitham RH
    Ann Neurol; 1998 Jan; 43(1):79-87. PubMed ID: 9450771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-1a during a first demyelinating event.
    Esmonde TF
    N Engl J Med; 2001 Jan; 344(3):229; author reply 229-30. PubMed ID: 11188841
    [No Abstract]   [Full Text] [Related]  

  • 16. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 17. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 18. Interferon beta in multiple sclerosis.
    Arnason BG
    Neurology; 1993 Apr; 43(4):641-3. PubMed ID: 8469315
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.